TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31086540
Drug: Multidisciplinary comprehensive
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary comprehensive respiratory rehabilitation in addition to NIPPV and medicines and oxygen therapy (Intervention Group-B)
Study: 31086540
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (medicines and oxygen therapy)
Study: 23265346
Drug: Colchicine 0.5
Normalized name: colchicine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.5 mg/day
Study: 23265346
Drug: Colchicine 0.5
Normalized name: colchicine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.5 mg/day (on-treatment analysis)
Study: 23265346
Drug: No colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No colchicine (on-treatment analysis)
Study: 21358204
Drug: XELOX (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX (oxaliplatin + oral capecitabine)
Study: 14585280
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PB and demethylating agents
Study: 14585280
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of a demethylating agent and HDAC inhibitors
Study: 10670599
Drug: Standard nomogram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nomogram for managing anticoagulation therapy (Group A, n = 10)
Study: 10670599
Drug: No nomogram
Approvals — FDA: no, EMA: no, PMDA: no
Description: No nomogram for managing anticoagulation therapy (Group B, n = 10)
Study: 2200995
Drug: Cefuroxime-axetil (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime-axetil (250 mg bid)
Study: 2200995
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid (500 mg/125 mg bid)
Study: 31150573
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (gemcitabine 1 g/m² on days 1 and 8, cisplatin 80 mg/m² on day 1, every 3 weeks for three cycles) plus concurrent chemoradiotherapy
Study: 31150573
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (gemcitabine and cisplatin) plus concurrent chemoradiotherapy
Study: 31150573
Drug: Standard-therapy (chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-therapy (chemoradiotherapy alone)
Study: 26513512
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy and Exposure therapy
Study: 17990450
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with Chinese herbal medicine (Kangliu Zengxiao Decoction during chemotherapy and Feiyanning Decoction after chemotherapy)
Study: 17990450
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with Chinese herbal medicine
Study: 7919085
Drug: 24-hour sodium
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24-hour sodium excretion rates
Study: 7919085
Drug: 24-hour magnesium/creatinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour magnesium/creatinine excretion ratio
Study: 7919085
Drug: 24-hour sodium
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24-hour sodium excretion rate
Study: 7919085
Drug: 24-hour taurine
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 24-hour taurine excretion rate
Study: 29705158
Drug: Functional electrostimulation
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional electrostimulation + standard medical treatment
Study: 29705158
Drug: Calisthenic exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calisthenic exercises + standard medical treatment
Study: 18812677
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment (control group)
Study: 11192143
Drug: Citalopram oral
Normalized name: citalopram Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram oral solution (10 mg/5 mL), 60 mg dose
Study: 11192143
Drug: Citalopram tablet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram tablet, 60 mg dose
Study: 2418295
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous amrinone (200-400-800 micrograms/kg/h)
Study: 2418295
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous amrinone (800-1600-3200 micrograms/kg/h)
Study: 22298163
Drug: One venous
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One venous line cannulation with heparin
Study: 22298163
Drug: Separate cannulation
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate cannulation without heparin
Study: 15761020
Drug: G-CSF during
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF during chemotherapy (Group B)
Study: 15761020
Drug: G-CSF after
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF after chemotherapy until day 28 or recovery (Group C)
Study: 15761020
Drug: G-CSF during
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF during and after chemotherapy (Group D)
Study: 15761020
Drug: No G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No G-CSF (Group A)
Study: 15761020
Drug: G-CSF during
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF during chemotherapy (Groups B + D)
Study: 15761020
Drug: G-CSF after
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF after chemotherapy (Groups C + D)
Study: 15761020
Drug: G-CSF after
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF after chemotherapy
Study: 9797551
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution alone (Control)
Study: 2468933
Drug: Flecainide 100
Normalized name: flecainide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide 100 mg b.i.d.
Study: 2468933
Drug: Quinidine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine 500 mg b.i.d.
Study: 2468933
Drug: Flecainide 100
Normalized name: flecainide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide 100 mg b.i.d. (after dose adjustment)
Study: 2468933
Drug: Quinidine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine 500 mg b.i.d. (before and after dose adjustment)
Study: 23294276
Drug: Tofacitinib 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 15 mg twice daily
Study: 28124822
Drug: Liraglutide/metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide/metformin
Study: 11703422
Drug: Placebo/metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/metformin
Study: 24226297
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of the intervention (three or more components).
Study: 23241063
Drug: Ultrasound-guided cervical
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided cervical periradicular steroid injection (US-CPSI)
Study: 21397530
Drug: Invasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive treatment (endovascular and/or surgical)
Study: 16192421
Drug: Standard-dose hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose hemodialysis
Study: 12783106
Drug: Enoxaparin monotherapy
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin monotherapy (1 mg/kg twice daily for 14 days, then randomized to 1.0 mg/kg vs. 1.5 mg/kg once daily)
Study: 16444853
Drug: Enoxaparin monotherapy
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin monotherapy
Study: 12783106
Drug: Intravenous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous unfractionated heparin as a bridge to warfarin (target INR 2.0-3.0)
Study: 12783106
Drug: Intravenous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous unfractionated heparin as a bridge to warfarin
Study: 10993961
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with mitomycin C (15 mg/M(2) on the first and sixth week of radiotherapy)
Study: 8791049
Drug: estramustine phosphate
Normalized name: Estramustine phosphate
DrugBank: Estramustine phosphate (DB14674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estramustine phosphate 600 mg/m2 orally daily for 2 years
Study: 8791049
Drug: cyclophosphamide 1
Normalized name: cyclophosphamide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclophosphamide 1 g/m2 intravenously every 3 weeks for 2 years
Study: 8791049
Drug: no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment (observation only)
Study: 1538722
Drug: Fluconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200 mg per day given orally)
Study: 1538722
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (1 mg per kilogram of body weight per week given intravenously)
Study: 6548925
Drug: Antacid A
Normalized name: Antacid Anti-Gas
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid A (aluminium‐magnesium hydroxide codried gel, aluminium hydroxide, calcium carbonate)
Study: 6548925
Drug: Antacid A
Normalized name: Antacid Anti-Gas
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid A
Study: 30264287
Drug: Control (pre‐preparation)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (pre‐preparation)
Study: 19215577
Drug: Fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 80 mg qd
Study: 16498265
Drug: L-NAME (NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME (NO synthase inhibitor)
Study: 16498265
Drug: Aspirin (prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (prostaglandin inhibitor)
Study: 16498265
Drug: Cetirizine (H1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (H1 receptor antagonist)
Study: 14623703
Drug: HuMax-CD4 20
Normalized name: Humax-cd4
DrugBank: Zanolimumab (DB17376)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuMax-CD4 20 mg
Study: 14623703
Drug: HuMax-CD4 80
Normalized name: Humax-cd4
DrugBank: Zanolimumab (DB17376)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuMax-CD4 80 mg
Study: 14623703
Drug: HuMax-CD4 160
Normalized name: Humax-cd4
DrugBank: Zanolimumab (DB17376)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuMax-CD4 160 mg
Study: 14623703
Drug: HuMax-CD4 280
Normalized name: Humax-cd4
DrugBank: Zanolimumab (DB17376)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuMax-CD4 280 mg
Study: 8018638
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of mifepristone
Study: 3901936
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg prostaglandin E2 (PGE2) gel
Study: 23981321
Drug: Word-learning training,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Word-learning training, 2-weekly sessions across 10 weeks
Study: 20812958
Drug: L-carnitine supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplement (1000 mg/d for 12 weeks)
Study: 20812958
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no L-carnitine supplement)
Study: 10948088
Drug: N(G)‐monomethyl‐L‐arginine (L‐NMMA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)‐monomethyl‐L‐arginine (L‐NMMA) (3 mg/kg per hour)
Study: 10948088
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (1 to 3 mg/h)
Study: 8980592
Drug: Maloprim (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maloprim (6.25 mg pyrimethamine + 50 mg dapsone for children under 10 years, and 12.5 mg pyrimethamine + 100 mg dapsone for children 10 or more years old as a single dose)
Study: 3914621
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of retinoids
Study: 3914621
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of retinoids
Study: 3914621
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid administration
Study: 31580693
Drug: I-gel mask
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-gel mask
Study: 31580693
Drug: Both I-gel
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both I-gel and Baska masks
Study: 17219216
Drug: MDMA (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (75 and 50 mg)
Study: 11993408
Drug: Potassium losartan
Normalized name: Losartan Potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium losartan 50 mg per day
Study: 8188888
Drug: Topical calcitriol
Normalized name: calcitriol Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcitriol (3 micrograms/gm) applied twice daily for 6 weeks
Study: 3796920
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of prostaglandin E1 analogue (ONO-802)
Study: 30866893
Drug: HBV vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccination (94.2% reported vaccination; 4.7% with 2 doses, 58.1% with 3 doses, 37.2% took a booster)
Study: 30127247
Drug: EGCG (752
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG (752 mg)
Study: 30127247
Drug: Placebo (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (800 mg corn starch)
Study: 26961597
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of tranexamic acid (TXA) mixed in 100 mL normal saline
Study: 26961597
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of normal saline
Study: 25200415
Drug: QGE031 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: QGE031 (2 mg/kg)
Study: 25200415
Drug: QGE031 (0.1-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: QGE031 (0.1-10 mg/kg) or placebo (IV)
Study: 25200415
Drug: QGE031 (0.2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: QGE031 (0.2-4 mg/kg) or placebo (SC)
Study: 25200415
Drug: QGE031 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: QGE031 (10 mg/kg)
Study: 21166111
Drug: Once-daily Tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily Tacrolimus Extended Release (Tac ER)
Study: 21166111
Drug: Twice-daily Cyclosporine
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily Cyclosporine (CsA)
Study: 25247335
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg/day for 12 weeks)
Study: 9869176
Drug: Selenium (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (100 microg daily)
Study: 9869176
Drug: Beta-carotene (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (30 mg twice daily)
Study: 2517495
Drug: Oxindanac 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxindanac 200 mg thrice daily
Study: 2517495
Drug: Paracetamol 1
Normalized name: Paracetamol 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1 g thrice daily (positive control)
Study: 194506
Drug: EG626 (cAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: EG626 (cAMP phosphodiesterase inhibitor)
Study: 31515921
Drug: Oral IgG
Normalized name: Human IGG
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral IgG
Study: 31515921
Drug: Non-oral IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-oral IgG
Study: 27077121
Drug: VIS410 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIS410 (2 mg/kg - 50 mg/kg)
Study: 27077121
Drug: VIS410 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIS410 (30 mg/kg)
Study: 27077121
Drug: VIS410 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIS410 (50 mg/kg)
Study: 19254816
Drug: Yacon syrup
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yacon syrup (0.14 g fructooligosaccharides/kg/day)
Study: 19254816
Drug: Yacon syrup
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yacon syrup (0.29 g fructooligosaccharides/kg/day)
Study: 17197807
Drug: CD4 cell
Normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD4 cell count and plasma HIV‐1 RNA (pVL)‐guided treatment interruptions (GTI)
Study: 17197807
Drug: Standard antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiretroviral therapy (control group)
Study: 15976210
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg of hyperbaric ropivacaine 0.5% (group Ropi‐7.5, n = 31)
Study: 15976210
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of hyperbaric levobupivacaine 0.5% (group Levo‐5, n = 30)
Study: 15976210
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg of hyperbaric levobupivacaine 0.5% (group Levo‐7.5, n = 30)
Study: 10528287
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) administered orally at 1 g twice daily
Study: 10528287
Drug: Systemic cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic cyclosporin A (CSA) with dosage varying between 100 and 500 mg daily based on blood trough levels of 120-150 ng/ml
Study: 8895005
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose interferon-alpha 2b 3 MU thrice weekly for 1 year
Study: 8895005
Drug: Titrated dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated dose interferon starting at 5 MU thrice weekly for 1 year
Study: 6133481
Drug: Ranitidine 100
Normalized name: ranitidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 100 mg and 50 mg
Study: 31082669
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Radium-223 55 kBq/kg every six weeks × 5 doses plus docetaxel 60 mg/m2 q3w × 10 doses)
Study: 31082669
Drug: Docetaxel alone
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel alone (75 mg/m2 every 3 weeks)
Study: 22267599
Drug: Azithromycin (Azi)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (Azi) 250 mg/day
Study: 20123314
Drug: Rate-adaptive pacing
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rate-adaptive pacing (RAP) therapy
Study: 15833782
Drug: Diphenhydramine-morphine mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine-morphine mixture (4.8:1 ratio)
Study: 15833782
Drug: Diphenhydramine-morphine mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine-morphine mixture (1.2:1 ratio)
Study: 31446213
Drug: Olaparib monotherapy
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib monotherapy (300 mg twice daily)
Study: 29465210
Drug: Remaxol included
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remaxol included in infusion therapy before anesthesia
Study: 26072359
Drug: Worth the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Worth the Walk intervention (hour-long sessions twice weekly for four weeks)
Study: 23208880
Drug: YF vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: YF vaccine and Ig
Study: 23208880
Drug: YF vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: YF vaccine and saline placebo
Study: 21802442
Drug: Intranasal methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal methamphetamine (0, 5, 10, 20 and 30 mg) during atomoxetine maintenance (80 mg/day)
Study: 21802442
Drug: Intranasal methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal methamphetamine during atomoxetine maintenance (80 mg/day)
Study: 19608354
Drug: Bupropion combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion combined with cognitive behavioral therapy and contingency management
Study: 15139054
Drug: Docetaxel (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (30 mg/m2 weekly for 6 weeks)
Study: 3583091
Drug: DA agonists
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA agonists (DA, L-dopa, L-dopa plus carbidopa, nomifensine, amphetamine)
Study: 25640832
Drug: Fast Track
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast Track intervention (10 years of treatment with various services)
Study: 19660594
Drug: Moderate-dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose statin therapy (simvastatin 20 to 40 mg/day in IDEAL and atorvastatin 10 mg/day in TNT)
Study: 15769695
Drug: Heparin Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin Management Test (HMT)
Study: 27760084
Drug: Gua sha
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Gua HC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gua sha therapy plus conventional treatment for 8 weeks